Award of Share Options

Sareum Holdings PLC

("Sareum" or the "Company")

Award of Share Options

Transfer of Shares

Exercise of Warrants

Issue of Adviser Fee Shares

Cambridge, UK, 16 December 2024 - Sareum Holdings plc (AIM: SAR), a biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer, announces the grant of options to Tim Mitchell (Chief Operating Officer), John Reader (Founder and Chief Scientific Officer) and Stephen Parker (Executive Chairman)  over, in aggregate, 4,400,000 ordinary shares of 1.25 pence each in the capital of the Company ("Ordinary Shares") (the "Options"). A total of 890,000 Options will be granted under the Company's Enterprise Management Incentive ("EMI") plan, and the remaining Options will be granted under an unapproved share option scheme on identical terms to the EMI options, as further detailed below.

The Options have an exercise price of 30.48 pence, being equal to a premium of 15.0% to the closing mid-market price of an Ordinary Share on 13 December 2024, being the last trading day before the award of the Options. The Options will be structured to vest from 16 December 2027 and will lapse on the fifth anniversary of the date of grant. Details of the individual tranches are as follow:

·    Tranche 1: 50% of the Options will vest on 16 December 2027

·    Tranche 2: 50% of the Options will vest on 16 December 2027 providing the Company has met certain commercial and technical milestones

Details of the Options award is detailed in the table below:

Following the grant of the new Options, a total of 7,430,058 options are outstanding, representing approximately 6.0% of the Company's issued share capital following Admission.

Transfer of Shares

The Company also announces that Dr. Tim Mitchell, has transferred 451,960 of his Ordinary Shares to his spouse, resulting in both Dr Mitchell and his spouse holding 651,960 Ordinary Shares, representing, in aggregate, approximately 1.04% of the Company's issued share capital following Admission.

Exercise of Warrants

The Company announces that it has received an exercise of warrants notice to subscribe for a total of 159,091 new Ordinary Shares at a price of 22.5 pence per new Ordinary Share for a total consideration to the Company of £35,795.48.

Issue of Adviser Fee Shares

Finally, the Company announces that it has issued 22,222 Ordinary Shares to an adviser to settle amounts due in relation to advice provided.

Admission and Total Voting Rights

The Company has applied for 181,313 new Ordinary Shares to be to be admitted to trading on AIM ("Admission") by 8.00 a.m. on or around 20 December 2024.

The new Ordinary Shares will, when issued, be credited as fully paid and will rank pari passu in all respects with the existing Ordinary Shares of the Company including the right to receive all dividends or other distributions made, paid or declared in respect of such shares after Admission.

Following Admission, the total number of Ordinary Shares in issue will be 124,927,651 and the total number of voting rights will thereafter be 124,927,651 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

For further information, please contact: 

About Sareum

Sareum (AIM: SAR) is a biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer.

The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases, including psoriasis, and has completed Phase 1 clinical development.

Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy.

Sareum Holdings plc is based in Cambridge, UK, and is quoted on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com.

PDMR Notification Form:

The below form is disclosed in accordance with the requirements of the EU's Market Abuse Regulation and in relation to certain dealings by directors pursuant to the Director Subscription and issue of Salary Conversion Shares:

END